This document has been prepared in accordance with accounting principles and practices generally accepted in Japan, and translated for reference only from the original Japanese version. The Company gives no warranty with respect to its correctness.

Oct. 25, 2011

Takara Holdings Inc.


Revision of Consolidated Business Results Forecast for the First Half
of the Fiscal Year Ending March 31, 2012

In light of recent business result trends, the Company revised the business results forecast for the first half of the fiscal year ending March 31, 2012 (from April 1, 2011, to March 31, 2012) that it announced on September 20, 2011, as stated below.

1. Revised figures for the business results forecast for the first half of the fiscal year ending March 31, 2012 (from April 1, 2011, to September 30, 2011)

(Millions of yen / %)

2. Reason for revision

The Company announced a revised consolidated business results forecast on September 20, 2011. Subsequently, however, further detailed analysis has resulted in an outlook that surpasses the previously announced forecast for net sales, operating income, ordinary income, and net income.
          For net sales, the outlook for the Takara Bio Group is slightly lower than the previously announced forecast. However, for the Takara Shuzo Group, the outlook is higher than the forecast formulated on September 20, 2011. As a result, the outlook for consolidated net sales is ¥100 million (0.1%) higher than the previously announced forecast.
          As for earnings, due to higher net sales from the Takara Shuzo Group and a decrease in the cost of sales ratio of the Takara Bio Group, increases of ¥300 million (10.0%) in operating income, ¥300 million (9.7%) in ordinary income, and ¥200 million (28.6%) in net income compared to the previously announced forecast are expected, and year-on-year increases in operating income and ordinary income are expected.

Moreover, today the Company’s consolidated subsidiary Takara Bio Inc. (Tokyo Stock Exchange Mothers, securities code number: 4974), which operates a Biomedical business, has also announced a revision of its business results forecast for first half of the fiscal year ending March 31, 2012.

3. Full-year business results forecast for the fiscal year ending March 31, 2012

The Company is currently undertaking detailed analysis of a revision of consolidated business results for the full fiscal year, including whether or not revision is necessary. The Company will make an announcement in this regard when it announces its business results for the first half on November 4, 2011.

* The above-mentioned forecasts have been prepared based on the information available as of the date of announcement of this document and could differ from the business result figures scheduled to be announced on November 4, 2011.